The opioid epidemic continues to affect hundreds of thousands of people, but there may be hope for the future with a new, non ...
The FDA has approved a new non-opioid prescription medication, Journavx for adults with moderate to severe acute pain.
The US Food and Drug Administration has approved suzetrigine (Journavx) 50 mg oral tablets, a first-in-class non-opioid ...
The new FDA-approved pain drug is suzetrigine, with the brand name Journavx. Suzetrigine is designed to alleviate moderate to ...
FDA Approves Non-Opioid Treatment for Moderate to Severe Acute Pain as Agency Continues to Take Steps to Support New ...
Leerink Partners analyst David Risinger has reiterated their bullish stance on VRTX stock, giving a Buy rating on January 31.Maximize Your ...
Vertex (VRTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...
Vertex Pharmaceuticals (VRTX) stock has performed strongly since the turn of the year, gaining 14.6% and vastly outperforming ...
The U.S. Food and Drug Administration has approved a novel prescription pain medication that targets sodium channels involved ...
These launches are positioned for multi-blockbuster status, thanks to their promise of fulfilling unmet needs, impacting ...
President Donald Trump on Saturday finalized tariffs, set to go into effect on Tuesday, at 10 percent on all Chinese goods, ...
The FDA has approved the first new type of pain medication in more than two decades — and it’s not an opioid. The drug is Suzetrigine under the brand name Journavx. It is now FDA-approved to treat ...